Pretreatment hydronephrosis associated with inferior overall survival in patients with muscle-invasive bladder cancer
Hydronephrosis linked to worse survival in bladder cancer patients
This meta-analysis of 8586 adults with muscle-invasive bladder cancer (MIBC) found that pretreatment hydronephrosis is significantly associa…
A large study finds that swollen kidneys before radiation treatment are linked to poorer survival outcomes for those with muscle-invasive bl…
Hyperthermic intravesical chemotherapy shows comparable efficacy to BCG with lower dysuria rates in NMIBC
Trial Shows HIVEC and BCG Have Similar Results for Bladder Cancer
This meta-analysis of 820 patients compared hyperthermic intravesical chemotherapy (HIVEC) to bacillus Calmette-Guérin (BCG) for non-muscle …
A review of 820 patients shows that two different bladder cancer treatments have similar success rates but differ in patient comfort.
Adjuvant PD-1 inhibitors significantly improve disease-free survival in patients with resected high-risk muscle-invasive bladder cancer
PD-1 Inhibitors Improve Survival for Muscle Invasive Bladder Cancer
This meta-analysis of Phase 3 trials indicates that adjuvant nivolumab or pembrolizumab improves disease-free survival (DFS) in patients wit…
New data suggests that PD-1 inhibitors like nivolumab or pembrolizumab may improve disease-free survival for patients with high-risk bladder…
High PTTG1 expression correlates with poorer survival and advanced disease in various solid tumors
High levels of PTTG1 protein linked to worse cancer outcomes
This meta-analysis of 22 studies from 21 articles analyzed the prognostic value of PTTG1 expression across multiple solid tumors. High PTTG1…
A review of 22 studies shows that high levels of the PTTG1 protein are linked to shorter survival times in several types of solid tumors.
Spontaneous regression observed in a patient with cystic renal cell carcinoma
Kidney tumor shows spontaneous regression before surgery for diagnosis
A case report describes a patient with a cystic mass in the left kidney that exhibited spontaneous regression following an initial period of…
A rare case of kidney cancer showed unexpected shrinking before surgery, highlighting why early intervention is vital for diagnosing complex…
Neoadjuvant chemoimmunotherapy achieves higher pathological complete response rates than chemotherapy alone in muscle-invasive bladder cancer
Chemoimmunotherapy Shows Higher Response Rates in Bladder Cancer
This network meta-analysis of 2234 patients with muscle-invasive bladder cancer compares neoadjuvant chemoimmunotherapy (NICT), chemotherapy…
A new analysis shows that combining chemotherapy and immunotherapy may lead to higher response rates for patients with muscle-invasive bladd…
Fianlimab plus cemiplimab showed objective response rates of 20% to 33% in advanced solid tumors during a Phase 1 study.
Early trial shows new cancer drug combo helps some patients with advanced disease
This Phase 1, first-in-human dose-expansion study evaluated fianlimab 1600 mg plus cemiplimab 350 mg in patients with advanced non-small cel…
A new drug combination helped some patients with advanced lung, kidney, head and neck, or skin cancer shrink their tumors in early testing.
ADRB1 and ADRB2 antihypertensive target perturbations associated with increased clear cell renal cell carcinoma risk
Genetic markers linked to blood pressure drugs raise kidney cancer risk
This meta-analysis of Mendelian randomization and colocalization analyses found that genetic perturbations equivalent to antihypertensive dr…
Genetic data suggests certain blood pressure targets may increase clear cell renal cell carcinoma risk, a finding that warrants attention fo…
Percutaneous thermal ablation shows higher local recurrence than robot-assisted partial nephrectomy for localized renal cell carcinoma
Meta-analysis shows higher local recurrence risk with thermal ablation for kidney cancer
This systematic review and meta-analysis of 2,516 patients with localized renal cell carcinoma compared percutaneous thermal ablation to rob…
A large analysis of kidney cancer treatments found thermal ablation had higher local recurrence rates than partial nephrectomy, though overa…
Metachronous non-muscle invasive bladder cancer after UTUC has worse recurrence and progression with BCG than primary disease
Doctors found that bladder cancer returning later has higher risk of coming back again
This systematic review and meta-analysis of 1292 patients found that metachronous non-muscle invasive bladder cancer after upper tract uroth…
A large review shows bladder cancer returning after a previous kidney cancer treatment is more likely to grow back. This group also has a lo…
Case report of 3-year-old girl with bilateral Wilms tumor and TP53 mutation treated with VAD chemotherapy and surgery
3-year-old girl with TP53 mutation and bilateral Wilms tumor died after treatment
This case-based review describes a single 3-year-old girl with bilateral Wilms tumor and a TP53 mutation treated under the Chinese Children …
A single case report describes a 3-year-old girl with bilateral Wilms tumor and a TP53 mutation who died despite aggressive chemotherapy and…
Case review of epithelial-type Wilms tumor in a 23-year-old female with clear surgical margins
A rare kidney tumor in a young adult was removed with clear margins and no spread
This case review describes a 23-year-old female who underwent right radical nephrectomy for a rare epithelial-type Wilms tumor. Histopatholo…
A 23-year-old woman had a rare kidney tumor removed. The surgery showed clear edges and no spread. This case highlights the need for awarene…
All Urologic Neoplasms Articles
- Pretreatment hydronephrosis associated with inferior overall survival in patients with muscle-invasive bladder cancer
- Hyperthermic intravesical chemotherapy shows comparable efficacy to BCG with lower dysuria rates in NMIBC
- Adjuvant PD-1 inhibitors significantly improve disease-free survival in patients with resected high-risk muscle-invasive bladder cancer
- High PTTG1 expression correlates with poorer survival and advanced disease in various solid tumors
- Spontaneous regression observed in a patient with cystic renal cell carcinoma
- Neoadjuvant chemoimmunotherapy achieves higher pathological complete response rates than chemotherapy alone in muscle-invasive bladder cancer
- Fianlimab plus cemiplimab showed objective response rates of 20% to 33% in advanced solid tumors during a Phase 1 study.
- ADRB1 and ADRB2 antihypertensive target perturbations associated with increased clear cell renal cell carcinoma risk
- Percutaneous thermal ablation shows higher local recurrence than robot-assisted partial nephrectomy for localized renal cell carcinoma
- Metachronous non-muscle invasive bladder cancer after UTUC has worse recurrence and progression with BCG than primary disease
- Case report of 3-year-old girl with bilateral Wilms tumor and TP53 mutation treated with VAD chemotherapy and surgery
- Case review of epithelial-type Wilms tumor in a 23-year-old female with clear surgical margins
- Angiogenic ccRCC tumors show higher pancreatic metastasis rate in phase II trial
- FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
- BCG plus mitomycin did not improve disease-free survival versus BCG alone in high-risk non-muscle-invasive bladder cancer patients
- Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
- Meta-analysis compares bladder preservation therapy vs cystectomy in elderly muscle-invasive bladder cancer
- Systematic review and meta-analysis compares intravesical gemcitabine/docetaxel versus BCG for non-muscle-invasive bladder cancer
- UK trial reports 4-year event-free survival of 63% and overall survival of 68% in relapsed Wilms tumour patients
- Kidney-directed SBRT shows modest renal function decline in inoperable patients
- Meta-analysis shows active surveillance and ablative therapy for small renal masses have comparable cancer-specific survival
- Prospective study shows active surveillance yields high survival for small renal masses under 2 cm
- Case report and literature review on mosaic DICER1 mutations and disease stability in a 6-month-old boy
- Narrative review suggests adjuvant pembrolizumab benefits selected high-risk renal cell carcinoma patients
- Open-sourcing data and annotations for renal cell carcinoma yielded 142 annotated CT scans from 101 patients
- Hong Kong consensus statement updates management for locally advanced and metastatic renal cell carcinoma
- Office-based holmium-YAG TULA shows feasibility and safety for recurrent NMIBC in a high-risk cohort
- Real-world analysis finds 34% grade 3-4 adverse events in mRCC patients on immune-based combos
- Comprehensive review compares ICI-based regimens and ICI-TKI combinations against sunitinib in metastatic renal cell carcinoma
- Low ipilimumab trough concentration linked to worse progression-free survival in metastatic clear cell renal cell carcinoma
- Phase 3 RCT Shows Perioperative Enfortumab Vedotin and Pembrolizumab Benefit Muscle-Invasive Bladder Cancer
- Targeted therapy versus non-targeted therapy in renal cell carcinoma patients
- Neoadjuvant nivolumab alone or with ipilimumab in cisplatin-ineligible muscle-invasive bladder cancer
- Durvalumab plus chemotherapy improves event-free and overall survival in muscle-invasive bladder cancer compared to chemotherapy alone
- Predictors of pathological upstaging in clinical stage T1 renal cell carcinoma include male gender, age, and irregular margins
- Simlukafusp alfa plus atezolizumab with or without bevacizumab shows antitumor activity in metastatic renal cell carcinoma
- Late Wilms tumor recurrence observed 32 years after diagnosis in a single case report
- CFP10 immunohistochemistry shows high sensitivity for renal tuberculosis in surgical specimens
- Adjuvant intravesical BCG versus Epirubicin in intermediate-risk non-muscle invasive bladder cancer
- Meta-analysis shows ERAS care improves recovery and reduces complications in laparoscopic nephrectomy for renal cancer
- Phase II trial finds adding gemcitabine to cisplatin-radiotherapy does not improve 2-year disease-free survival in muscle-invasive bladder cancer
- Audit plus peer comparison improved documentation of tumour features and resection completeness in non-muscle-invasive bladder cancer surgery
- Neoadjuvant sacituzumab govitecan plus pembrolizumab shows 39% clinical complete response in MIBC
- Spinal anesthesia associated with lower recurrence than general anesthesia in non-muscle invasive bladder cancer
- CD8 PET imaging shows modest correlation with biopsy CD8 counts in solid tumor patients on immunotherapy
- PI3K-AKT-mTOR pathway activation linked to renal cell carcinoma progression in review